Metraipolis › archive › dc_d2de56d269c2
Association for Molecular Pathology v. Myriad Genetics, Inc. — Wikipedia (en)
- Source
- Wikipedia (en)
- Original
- https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc
- License (as archived)
- CC-BY-SA-4.0
- Archived
- 2026-11-10T04:47:04.369Z
- SHA-256 of the archived text
97a7510605f3202887f26918d55486163f9a59fb8cc5fa9ee287c377eec4e80d- Stable URL of this page
https://metraipolis.com/documento/dc_d2de56d269c2
How to cite
Association for Molecular Pathology v. Myriad Genetics, Inc. — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_d2de56d269c2 (Metraipolis archive dc_d2de56d269c2, sha256 97a7510605f3202887f26918d55486163f9a59fb8cc5fa9ee287c377eec4e80d)
BibTeX
@misc{dcd2de56d269c2,
title = {Association for Molecular Pathology v. Myriad Genetics, Inc. — Wikipedia (en)},
howpublished = {Wikipedia (en)},
url = {https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc},
note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_d2de56d269c2; sha256 97a7510605f3202887f26918d55486163f9a59fb8cc5fa9ee287c377eec4e80d},
year = {2026}
}Archived text
Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), was a Supreme Court case, which decided that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated." However, the Court allowed patenting of complementary DNA, which contains exactly the same protein-coding base pair sequence as the natural DNA, albeit with introns removed. The lawsuit in question challenged the validity of gene patents in the United States, specifically questioning certain claims in issued patents owned or controlled by Myriad Genetics that cover isolated DNA sequences, methods to diagnose propensity to cancer by looking for mutated DNA sequences, and methods to identify drugs using isolated DNA sequences. Prior to the case, the U.S. Patent Office accepted patents on isolated DNA sequences as a composition of matter. Diagnostic claims were already under question through the Supreme Court's prior holdings in Bilski v. Kappos and Mayo v. Prometheus. Drug screening claims were not seriously questioned prior to this case. Notably, the original lawsuit in this case was not filed by a patent owner against a patent infringer, but by a public interest group (American Civil Liberties Union) on behalf of 20 medical organizations, researchers, genetic counselors, and patients as a declaratory judgement. The case was originally heard in Southern District Court of New York. The District Court ruled that none of the challenged claims were patent eligible. The majority opinion called patenting isolated or purified natural products a “lawyer's trick” to circumvent the prohibitions on the direct patenting of products of nature. Myriad then appealed to the United States Court of Appeals for the Federal Circuit (CAFC). The Federal Circuit reversed the district court in part and affirmed in part, ruling that isolated DNA, which does not occur by itself in nature, can be patented, and that the drug screening claims were valid, but that Myriad's diagnostic claims were not patentable. The CAFC considered the valid gene claims as directed toward compositions of matter rather than toward information, like the District Court did. On appeal, the Supreme Court vacated and remanded the case back to the Federal Circuit to reconsider the issues in light of Mayo v. Prometheus. On remand, the Federal Circuit held that Mayo v. Prometheus did not affect the outcome of the case, so the American Civil Liberties Union and the Public Patent Foundation filed a petition for certiorari. The Supreme Court granted certiorari and unanimously invalidated Myriad's claims to isolated genes. The Supreme Court held that merely isolating genes (even with introns removed), which are found in nature, does not make them patentable. However, the SCOTUS agreed with the "friend of the court" brief submitted by the USPTO, that complementary DNA should be patent eligible, because it does not exist in Nature but rather was "engineered by man", Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico). Fonte: Wikipedia in inglese, voce «Association for Molecular Pathology v. Myriad Genetics, Inc.» — https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc. Wikidata Q24910724: «2013 United States Supreme Court case» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q24910724 Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.?action=history). Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza. Estratto dell'introduzione non modificato nel contenuto; revisione 1376212129, consultata il 2026-11-10T04:44:01.733Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: f1e498c41a1b6e8cee24e8ae55fa1796b5d5b60c6bd040cc9073b808fccdedc3